CLDN6/GPC3/Mesothelin/AXL-CAR-NK Cell Therapy for Advanced Solid Tumors

This study is testing a type of personalized cell therapy (CAR-NK cell therapy) for people with advanced solid tumors, including ovarian cancer and other cancers. The therapy uses a patient's own immune cells (NK cells), which are modified in the lab to attack cancer cells expressing specific proteins. **You may be eligible if...** - You have advanced ovarian cancer or another cancer that expresses certain proteins (Claudin 6, GPC3, Mesothelin, or AXL) - Your expected survival is more than 12 weeks - Your heart, lungs, liver, and kidneys are functioning adequately - Lab testing confirms your modified immune cells meet activity thresholds **You may NOT be eligible if...** - Your tumor does not express the required target proteins - Your cancer cells cannot be detected or targeted by the engineered immune cells - You have had certain previous treatments that interfere Talk to your doctor to see if this trial is right for you.